TGTX BRIUMVI (Ublituximab) approved for MS on 12/28/2022! See the new label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761238s000lbl.pdf
Competitors:
To see the full table of PDUFAs with extra information, read our January Biotech PDUFAs Forum post article for subscribers. Learn more here about signing up for BPIQ.*
If you are serious about investing in biotech stocks BPIQ is the research companion that will take you to the next level.
Save yourself time by accessing our database of over 550 companies, 1,800+ of their drug assets, and tools including: Catalyst Calendar, Big Movers, Company Pipelines, and more!
P.S. We are currently running a sale - lock in the price before it's gone
See what our members are saying about us:
Mike from United States
“Really loving the site over the competitor... like the layout and speed over the competition...like the individual pages for each drug/treatment”
Carl from United States
“I like your service. I haven’t seen anyone else doing something similar...nothing like this available for retail.”
Essey from Canada
“Love what you’re doing, this website is awesome.”
James from United States
Great site and I see it’s a family run business, great job.”
Comments